Register for our EIS fund today
Click Here

The o2h therapeutics fund

An early stage EIS and/or SEIS investment fund backing biotech therapeutic and related AI opportunities with plug-in capabilities in Cambridge, UK/India and a bridge to the USA.

Minimum investment:

£25,000

Know more

Fund Overview

Fund Fund Overview
Min Investment £25,000, there is no maximum investment. The current EIS investment limit in any tax year is £1,000,000.
Fund Size £1,000,000 to start investing, with an initial target of £10,000,000
Tax Advantages If you are a UK tax payer, you maybe eligible for S/EIS tax relief on investment
Differentiation Grassroots working relationships providing early access to deals.
Diversification We will typically use your subscription to build a portfolio of 5-12 companies, which will likely be focused on therapeutic biotech and related AI opportunities
Liquidity Capital is returned to you only when we are able to sell the shares in your portfolio companies.
Expected Exit 5-8 years. We will seek to exit investments after 3 years to preserve any S/EIS reliefs. We may hold investments longer if the business case warrants this, for similar reasons we may exit businesses earlier than 3 years
Speed of Investments While we will aim to deploy capital in 12-18 months, we will only invest when we find suitably exciting opportunities, which may on occasion extend this period
Founders Investment Min. 10% of the first £2m deployed and then min. 2.5% of every investment.
Risks You should only subscribe if you able to bear losing your entire investment
Closing Dates 11 December 2018, 4 April 2019, 31 July 2019, 10 October 2019.

Investor Suitability

Which investor type best describes you?

I am a High Net-Worth Individual
  • I have an annual income of more than £100k or net assets of over £250k.
 Review & confirm

I am a Sophisticated Investor
  • I have sufficient experience with early-stage investment to certify as a sophisticated investor
Review & confirm

I am neither a High Net-Worth Individual nor a Self-Certified Sophisticated Investor.
  • I do not fit into either of the other categories.
 Review & confirm

The fund is only available to investors who wish to be treated as professional investors and are suitable to be classed as professional investors.

Self certification as a high net worth individual

I declare that I am a certified high net worth individual for the purposes of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005.

I understand that this means:

  1. I can receive financial promotions that may not have been approved by a person authorised by the Financial Conduct Authority;

  2. The content of such financial promotions may not conform to rules issued by the Financial Conduct Authority;

  3. I may lose significant rights;

  4. I may have no right to complain to either of the following:

    1. the Financial Conduct Authority; or

    2. the Financial Ombudsman Scheme;

  5. I may have no right to seek compensation from the Financial Services Compensation Scheme.

I am a certified high net worth individual because at least one of the following applies

  1. the property which is my primary residence or any loan secured on that residence;

  2. any rights of mine under a qualifying contract of insurance within the meaning of the Financial Services and Markets Act 2000 (Regulated Activities) Order 2001; or

  3. any benefits (in the form of pensions or otherwise) which are payable on the termination of my service or on my death or retirement and to which I am (or my dependants are), or may be, entitled.

I accept that I can lose my property and other assets from making investment decisions based on I accept that I can lose my property and other assets from making investment decisions based on financial promotions. financial promotions.

I am aware that it is open to me to seek advice from someone who specialises in advising on investments.

Sign by clicking here Sign by clicking here

Self certification as a high net worth individual

I declare that I am a self-certified sophisticated investor for the purposes of the Financial Services and Markets Act (Financial Promotion) Order 2005.

I understand that this means:

  1. I can receive financial promotions that may not have been approved by a person authorised by the Financial Conduct Authority;

  2. The content of such financial promotions may not conform to rules issued by the Financial Conduct Authority;

  3. I may lose significant rights;

  4. I may have no right to complain to either of the following:

    1. the Financial Conduct Authority; or

    2. the Financial Ombudsman Scheme;

  5. I may have no right to seek compensation from the Financial Services Compensation Scheme.

I am a self-certified sophisticated investor because at least one of the following applies:

I accept that I can lose my property and other assets from making investment decisions based on I accept that I can lose my property and other assets from making investment decisions based on financial promotions. financial promotions.

I am aware that it is open to me to seek advice from someone who specialises in advising on investments.

Self certification as a high net worth individual

Sorry, you are not eligible to invest in this fund

Register as an Investor

You are not eligible to register

A passion for

investing

o2h ventures Limited is regulated by the financial service authority to raise an early stage EIS compliant investment fund backing biotech therapeutic opportunities.

Our investments

Exonate

Exonate is a biopharmaceutical company focussed on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need.

Sentinel

From initial concept to the delivery of candidate drugs – we’re a drug discovery company specialising in cutting-edge cancer treatment.

Phoremost

PhoreMost® has developed a next-generation phenotypic screening platform called ‘SITESEEKER®’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.

Talisman

Talisman Therapeutics, a spinout from the University of Cambridge, is a stem cell research and development company committed to revolutionising the discovery of treatments for Alzheimer’s disease.

Oppilotech

Science-led ambitious start up focused on the development of antibacterial compounds with novel mechanisms of action against drug resistant organisms.

Absynth

Absynth Biologics discovers and develops vaccines and antibodies to prevent and treat bacterial infections; based on a platform for identifying novel protein antigen targets that harness the immune system.

Acacia Pharma

Acacia Pharma is a specialty pharmaceutical company focused on the development and commercialisation of new treatments for supportive care of patients with debilitating conditions arising as a consequence of surgery, cancer or cancer treatment.

LaborVoices

LaborVoices provides global brands and their supply chains what has been missing: an early warning system based on direct feedback from workers, by repeatedly polling workers through their mobile phones.

Iota

IOTA Pharmaceuticals has been established to bring you the tools and technologies for Fragment-based Drug Discovery(FBDD) and High-content Screening(HCS).

5 Alarm Bio

5 Alarm Bio is a company dedicated for designing anti-ageing therapies.

Small Pharma

Small Pharma is forging a new path in pharmaceutical development by bridging the gap between academia and industry.

Oxford Drug Design

Oxford Drug Design (formerly InhibOx) is a biotechnology company focused on internal drug discovery. The lead antibacterial programme has identified compounds with the potential to be developed into therapies for Gram-negative bacterial infections, including against strains resistant to multiple current antibacterial drug classes.

Arecor

A UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides.

Repositive

The Repositive platform enables researchers to browse through multiple repositories for the human genomic data they need to power their research.

Privitar

Privitar facilitates broader use of data while adopting an uncompromising approach to protecting confidential information.

Heartfelt Technologies

Heartfelt Technologies exists to help patients, their families, carers and doctors, to reduce hospital re-admission rates from congestive heart failure de-compensation.

Stemnovate

Stemnovate at Cambridge, UK are developing a ‘liver on a chip’ system supported by a $1m Innovate UK award. The platform is based on cutting edge stem cell and micro engineering platform technologies at University of Edinburgh and Cambridge University.

Metrion Biosciences

Metrion Biosciences is a UK-based Contract Research Organization (CRO) focussed on delivering a range of high quality ion channel drug discovery services.

Ventures news

18 Oct 2018

“Investment will accelerate the delivery of significantly improved therapeutic treatments and quality of life for people living with diabetes” Cambridge, UK., 10 September 2018: Arecor Ltd (“the Company”), the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, today announces that it has secured £6.0 million of investment from new and existing investors for the clinical development of the Company’s speciality pharma portfolio of proprietary diabetes products. This £6.0 million equity investment into Arecor was led by leading UK institutional investors, Calculus Capital, Downing Ventures, and Albion Capital with significant participation from Arecor’s existing investors. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures. Arecor’s next-generation diabetes product pipeline represents exciting new progress in the field of diabetes that will enable important new treatment regimens and offer greater control of blood glucose to diabetes patients, which is key to improving outcomes and quality of life. This pipeline includes:- @ Proprietary formulations of insulin analogues that are ultra-rapid acting and more closely match a healthy body’s physiological response to blood glucose, leading to better blood glucose (sugar) control – currently a significant challenge @ Highly concentrated rapid acting insulin optimised for the next generation of body-worn miniaturised delivery devices, including the artificial pancreas @ Stable aqueous ready to use glucagon used in an emergency to treat severe hypoglycaemia and enabling future use in bi-hormonal artificial pancreas systems These programmes will be progressed through development to demonstrate improved product profiles and health outcomes in human clinical trials.  In addition to these clinical programmes, the investment will allow Arecor to progress its pre-clinical pipeline of diabetes combination products, as well as a range of additional superior biotherapeutics addressing critical unmet needs in key disease areas. The management of diabetes is one of the major global health challenges.  Indeed, the International Diabetes Federation (“IDF”) estimates that there are nearly half a billion (425 million) people currently living with diabetes around the world* and the IDF further estimates that if the global direct and indirect healthcare costs from diabetes are included, the economic impact of diabetes exceeds $1trillion**. *  International Diabetes Federation. IDF Diabetes Atlas, 8th edition. International Diabetes Federation, 2017. Available at: http://www.diabetesatlas.org/ ** Bommer C., Heesemann E., Sagalova V., et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol 2017; 5: 423-30. The improved products, therapeutic pathways and personalised control that Arecor’s products can enable, will make a significant contribution to addressing this challenge.   Arecor will be taking its product portfolio into clinical development itself, however, the Company will ultimately look to partner with specialist diabetes companies for late stage clinical studies and global market access. The Company, which was originally based on unique protein chemistry technology and insights spun out from Unilever, has refined and developed these into the ArestatTM formulation technology platform. This platform has been used extensively to improve the solution properties of numerous protein, anti-body, vaccine and peptide formulations both in collaboration with pharmaceutical partners, as well as for Arecor’s own pipeline.  Arecor has established a proven track record in applying this technology platform to deliver superior biopharmaceutical product profiles across a broad range of therapeutic areas. Dr Sarah Howell, Chief Executive Officer at Arecor, commented: “We are delighted to have secured the investment that we need to progress our lead diabetes programmes through the key stages of clinical development.  With diabetes reaching epidemic proportions worldwide and with close to half a billion people living with the condition today, the opportunity of advancing our diabetes products into human clinical trials and their potential to significantly improve the treatment of this debilitating disease, represents a very exciting and ground-breaking proposition”. Alexander Crawford, Investment Director, Calculus Capital, added: “Arecor is applying its unique and highly regarded reformulation technology which will help transform the growing diabetes market. As lead investor, we believe this is an exciting new phase from Arecor in the development of their technology and strong growth potential.” Dr Christoph Ruedig, Partner, Albion Capital, said: “We have followed Arecor for some time and are excited by the societal value of its fast onset, short duration action insulin. Its technology is highly differentiated and the Company is leading the sector in the area of stabilising liquid formulations for injectable drugs. We look forward to working with the strong leadership team to bring this extraordinary proposition to fruition and in doing so, aid many diabetic patients across the UK and beyond.” Richard Lewis, Investment Director, Downing Ventures, concluded: “As an investment opportunity, Arecor combines a solid and high margin technology business alongside a proprietary product offering that fulfils major unmet medical need.  As a result, we believe that the diabetes pipeline should successfully attract quality international commercial partners. ” Arecor is one of o2h Ventures’ investment.

25 May 2018

Stemnovate which is advancing 'organ on chip' technology has closed its seed investment round with a team of eight angels led by team of o2h ventures, whose co-founder Sunil Shah is joining the board as chairman.Stemnovate specialises in stem cell research, cellular differentiation and microengineering. Its 'liver on a chip' technology has exciting potential for pre-clinical hepatotoxicity testing, replicating the microarchitecture and functions of the human liver and taking account of variation in patient's individual genetic backgrounds. Mr Shah, who is an MBA from Cambridge University is a serial entrepreneur who co-founded two companies in information technology and life sciences sector O2h ventures involves discovery services and collaboration, seeding drug discovery, academic in-licensing and bio-technology incubation.He said "current models for screening new drugs for liver toxicity are not predictive,there is an urgent need for the reliable screening technology before millions are invested into a clinical trial only to fail due to liver toxicity". For more information- Stemnovate Secure....

17 Apr 2018

In January, Exonate, one of o2h venture's investement, was approached by the British Business Bank to feature in a series of videos to highlight their Business Finance Guide. The British Business Bank and Angel Co Fund have provided valuable funding and support to Exonate and our investment was highlighted an excellent case study to promote the banks work. Sunil Shah, CEO, o2h Ventures and Peter Cowley of Angel Co Fund were invited to take part and spent time being filmed in The Bradfield Centre in the Cambridge Science park. Watch the video here Read the full article

@o2hventures

September 15th 2018 09:09:07

o2h is celebrating women’s open day on 22nd Sept ‘18 to inspire women in science, technology and enterprise https://t.co/HfDyStxUz1

@o2hventures

June 10th 2018 03:06:53

RT @OxDrugDes: Paul is at #ASMicrobe this week, track him down if you want to find out more about our exciting #antibiotics projects! #ASMm…

@o2hventures

June 4th 2018 05:06:22

RT @CJBS_VCW: Third place, Eye Bot, with Prashant Shah, Director of @o2hventures #CamVCW https://t.co/4hHXQfFKkt

@o2hventures

June 4th 2018 03:06:22

RT @JamieQuested: Great flight with @primeraair from @STN_Airport to Boston for #BIO2018. Strong East of England presence at this year’s co…

@o2hventures

June 2nd 2018 11:06:46

RT @CJBS_VCW: Our third judge is Prashant Shah
Director at @o2hventures . Having begun a career with the Strategy group at Accenture he bec…

@o2hventures

June 2nd 2018 11:06:15

RT @CJBS_VCW: And we’re off. Full house for our keynote speaker Sunil Shah, founder of @o2hventures #biotech #Healthcare https://t.co/CHplg …

@o2hventures

June 2nd 2018 11:06:45

RT @CJBS_EC: Nurturing great British therapeutics #innovation : we're delighted to launch our Venture Creation Weekend in #biotech and #hea…

@o2hventures

May 11th 2018 12:05:23

https://t.co/4BDPRCZlZ0

@o2hventures

May 9th 2018 11:05:05

Thanks for your support business weekly, it is going to be a challenge to get this site working again but honestly… https://t.co/htfsNxBEO9

@o2hventures

May 8th 2018 05:05:11

o2h acquires 2.76 acre heritage Hauxton Mill site, Cambridge, UK with plans to develop it into the o2h SciTech Park https://t.co/zID1XshZp7

o2h culture, people & careers.

Subscribe to our newsletter